JO3358B1 - معالجات حساسية العيون - Google Patents

معالجات حساسية العيون

Info

Publication number
JO3358B1
JO3358B1 JOP/2007/0103A JOP20070103A JO3358B1 JO 3358 B1 JO3358 B1 JO 3358B1 JO P20070103 A JOP20070103 A JO P20070103A JO 3358 B1 JO3358 B1 JO 3358B1
Authority
JO
Jordan
Prior art keywords
ocular allergy
allergy treatments
treatments
ocular
alcaftadine
Prior art date
Application number
JOP/2007/0103A
Other languages
English (en)
Inventor
Ingerman Avner
Megens Anton
Parasrampuria Jagdish
Janssens Frans
Original Assignee
Vistakon Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38468943&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3358(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vistakon Pharmaceutical Llc filed Critical Vistakon Pharmaceutical Llc
Application granted granted Critical
Publication of JO3358B1 publication Critical patent/JO3358B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع بتركيبات (Compositions)، مجموعات (Kits) وطرق (methods) لعلاج او منع حساسية والتهاب العين واعراضها تشمل الكافتادين (alcaftadine) او ملح مقبول دوائيا منه.
JOP/2007/0103A 2006-03-31 2007-04-01 معالجات حساسية العيون JO3358B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78818506P 2006-03-31 2006-03-31
US68801607A 2007-03-19 2007-03-19

Publications (1)

Publication Number Publication Date
JO3358B1 true JO3358B1 (ar) 2019-03-13

Family

ID=38468943

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2007/0103A JO3358B1 (ar) 2006-03-31 2007-04-01 معالجات حساسية العيون

Country Status (30)

Country Link
US (7) US8664215B2 (ar)
EP (2) EP2004196B1 (ar)
JP (3) JP5292277B2 (ar)
KR (1) KR101321731B1 (ar)
CN (1) CN102895234A (ar)
AR (1) AR060278A1 (ar)
AU (1) AU2007234957B2 (ar)
BR (1) BRPI0710085B8 (ar)
CA (1) CA2648115C (ar)
CL (1) CL2007000916A1 (ar)
CR (1) CR10414A (ar)
DK (2) DK3150209T3 (ar)
EA (1) EA016221B1 (ar)
EC (1) ECSP088786A (ar)
ES (2) ES2752823T3 (ar)
HK (1) HK1131331A1 (ar)
IL (1) IL194473A (ar)
JO (1) JO3358B1 (ar)
MX (1) MX2008012657A (ar)
MY (1) MY153669A (ar)
NI (1) NI200800261A (ar)
NO (1) NO341147B1 (ar)
NZ (1) NZ571690A (ar)
PE (1) PE20080053A1 (ar)
PL (2) PL2004196T3 (ar)
SG (1) SG170044A1 (ar)
TW (2) TWI450721B (ar)
UY (1) UY30254A1 (ar)
WO (1) WO2007117971A2 (ar)
ZA (1) ZA200809327B (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2752823T3 (es) 2006-03-31 2020-04-06 Vistakon Pharmaceuticals Llc Tratamiento de alergias oculares
AU2007243334A1 (en) 2006-04-26 2007-11-08 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling
AU2008325214A1 (en) * 2007-11-08 2009-05-14 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
EP3943069A1 (en) 2009-03-17 2022-01-26 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
US9409913B2 (en) * 2012-11-21 2016-08-09 Enaltec Labs Private Limited Polymorphic forms of alcaftadine
US9255105B2 (en) * 2012-12-06 2016-02-09 Enaltec Labs Private Limited Process of preparing alcaftadine
EP3496662A4 (en) 2016-08-12 2019-10-30 Silk Technologies Ltd. PROTEIN DERIVED FROM SILK FOR THE TREATMENT OF INFLAMMATION
JP7191022B2 (ja) * 2017-07-28 2022-12-16 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
WO2019026992A1 (ja) * 2017-08-03 2019-02-07 参天製薬株式会社 クロルヘキシジンを含有する医薬組成物
WO2019141563A1 (en) * 2018-01-18 2019-07-25 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
AU2021291684A1 (en) 2020-06-15 2022-12-08 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
JP2024508811A (ja) 2021-02-24 2024-02-28 オキュラ セラピューティクス，インコーポレイテッド 小管内デポーインサータ装置
MX2023011546A (es) 2021-04-01 2023-10-06 Alkem Laboratories Ltd Composiciones nasales que comprenden alcaftadina.
WO2024010044A1 (ja) * 2022-07-06 2024-01-11 ロート製薬株式会社 眼科組成物
WO2024010039A1 (ja) * 2022-07-06 2024-01-11 ロート製薬株式会社 眼科組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148903A (en) 1977-07-28 1979-04-10 Merck & Co., Inc. Antipsychotic, antiserotonin and antihistaminic pyrrolo[2,1-b][3]benzazepines
DE3134672A1 (de) 1981-09-02 1983-03-17 Boehringer Ingelheim KG, 6507 Ingelheim Heterocyclische verbindungen, ihre herstellung und verwendung
GB8900380D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
AU8902591A (en) * 1990-10-10 1992-05-20 Schering Corporation Substituted imidazobenzazepines and imidazopyridoazepines
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv History 11-) 4-Pipridinyl (-Imidazo] B-1, 2 [] 3 [Benzazepine, their preparation and pharmaceutical preparations containing them
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US20060100408A1 (en) * 2002-03-11 2006-05-11 Powell P M Method for forming contact lenses comprising therapeutic agents
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
US20070077303A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
BRPI0709549A2 (pt) 2006-03-17 2011-07-19 Johnson & Johnson Vision Care métodos para estabilizar composições instáveis oxidativamente
ES2752823T3 (es) 2006-03-31 2020-04-06 Vistakon Pharmaceuticals Llc Tratamiento de alergias oculares

Also Published As

Publication number Publication date
US20210030762A1 (en) 2021-02-04
US8664215B2 (en) 2014-03-04
CN102895234A (zh) 2013-01-30
JP6039716B2 (ja) 2016-12-07
CA2648115A1 (en) 2007-10-18
JP5292277B2 (ja) 2013-09-18
ES2594655T3 (es) 2016-12-21
BRPI0710085B8 (pt) 2021-05-25
JP2013144703A (ja) 2013-07-25
WO2007117971A3 (en) 2007-12-27
AR060278A1 (es) 2008-06-04
AU2007234957A1 (en) 2007-10-18
JP2009533333A (ja) 2009-09-17
CR10414A (es) 2009-02-23
ECSP088786A (es) 2009-01-30
US20170065605A1 (en) 2017-03-09
AU2007234957B2 (en) 2012-12-13
PE20080053A1 (es) 2008-03-10
ZA200809327B (en) 2009-12-30
US10617695B2 (en) 2020-04-14
US20240058355A1 (en) 2024-02-22
ES2752823T3 (es) 2020-04-06
NI200800261A (es) 2012-10-30
TWI450721B (zh) 2014-09-01
TW201446249A (zh) 2014-12-16
PL3150209T3 (pl) 2020-03-31
DK2004196T3 (en) 2016-09-05
EP2004196A2 (en) 2008-12-24
PL2004196T3 (pl) 2017-01-31
KR101321731B1 (ko) 2013-10-30
BRPI0710085B1 (pt) 2019-12-17
IL194473A (en) 2016-04-21
HK1131331A1 (en) 2010-01-22
IL194473A0 (en) 2009-08-03
US20230181594A1 (en) 2023-06-15
EP3150209B1 (en) 2019-07-24
MY153669A (en) 2015-03-13
US20080051385A1 (en) 2008-02-28
SG170044A1 (en) 2011-04-29
CL2007000916A1 (es) 2008-01-25
EP2004196B1 (en) 2016-06-29
UY30254A1 (es) 2007-08-31
EA200870396A1 (ru) 2009-04-28
TWI578990B (zh) 2017-04-21
NZ571690A (en) 2011-09-30
KR20080110881A (ko) 2008-12-19
WO2007117971A2 (en) 2007-10-18
EP3150209A1 (en) 2017-04-05
TW200815016A (en) 2008-04-01
EA016221B1 (ru) 2012-03-30
JP2015131820A (ja) 2015-07-23
NO341147B1 (no) 2017-09-04
US20140107102A1 (en) 2014-04-17
CA2648115C (en) 2015-03-24
BRPI0710085A2 (pt) 2011-08-23
US20120094978A1 (en) 2012-04-19
DK3150209T3 (da) 2019-10-28
NO20084593L (no) 2008-10-29
MX2008012657A (es) 2009-02-19

Similar Documents

Publication Publication Date Title
JO3358B1 (ar) معالجات حساسية العيون
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2007092622A3 (en) Compositions and methods for treating bone
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
EA200901486A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
TNSN08400A1 (en) Organic compounds and their uses
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MA32934B1 (ar) تركيبات مضادة ل hsp90
EA201170521A1 (ru) Новые соединения
MY149606A (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
IN2012DN00624A (ar)
WO2007084684A3 (en) Therapeutic uses of inhibitors of rtp801
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
EP2069377A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
EA200901484A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
AR111697A2 (es) Composición oftálmica para el tratamiento de las alergias oculares
WO2007108004A8 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases